Stay updated on Comparison of Pembrolizumab Timing in High-Risk Melanoma Clinical Trial
Sign up to get notified when there's something new on the Comparison of Pembrolizumab Timing in High-Risk Melanoma Clinical Trial page.

Latest updates to the Comparison of Pembrolizumab Timing in High-Risk Melanoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedA new page revision entry 'Revision: v3.3.3' was added; the items 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' were removed.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe history now shows updates to Contacts/Locations and Study Status (version 406) with entries dated 2025-11-15 and 2025-12-05.SummaryDifference0.1%

- Check41 days agoChange DetectedThe 2025-11-17 version adds Contacts/Locations and Study Status sections and records Revision: v3.3.2, while 2025-09-22 notes the deletion of Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedThe notice about lapse in government funding and operating status at the top of the page was removed.SummaryDifference0.1%

- Check62 days agoChange DetectedThe Record History shows a long sequence of versions from 2018 to 2025, with updates to Study Status and Contacts/Locations along with other sections.SummaryDifference0.0%

- Check91 days agoChange Detected- Added a prominent notice about potential outages due to lapse in government funding and updated operating status guidance. - Updated version from v3.1.0 to v3.2.0.SummaryDifference3%

Stay in the know with updates to Comparison of Pembrolizumab Timing in High-Risk Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Comparison of Pembrolizumab Timing in High-Risk Melanoma Clinical Trial page.